TAP EN Article Feed https://ascopost.com/ All the latest and greatest ASCO Post articles and news. Wed, 01 Jul 2026 04:15:16 +00:00 en-US hourly 1 Breast Cancer: Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease https://ascopost.com/news/june-2026/breast-cancer-palbociclib-based-regimen-approved-for-hr-positive-her2-positive-metastatic-disease/ Wed, 01 Jul 2026 04:15:16 +00:00 The ASCO Post In late June, the FDA approved palbociclib (Ibrance) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.

]]> Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy https://ascopost.com/news/june-2026/paving-new-roads-in-the-treatment-of-brain-metastases-with-implanted-tile-based-radiation-therapy/ Wed, 01 Jul 2026 03:43:45 +00:00 The ASCO Post Tile-based radiation therapy implanted at the time of resection outperformed standard postoperative stereotactic radiation therapy in the phase III Radiation One and Done Study (ROADS), improving surgical bed control and overall survival while maintaining a comparable safety profile, investigators reported at the 2026 ASCO Annual Meeting.

]]> Single-Fraction SBRT in Localized Prostate Cancer https://ascopost.com/news/july-2026/single-fraction-sbrt-in-localized-prostate-cancer/ Wed, 01 Jul 2026 04:04:44 +00:00 The ASCO Post Investigators attempted to determine whether single-fraction high-dose stereotactic body radiotherapy (SBRT) improved biochemical relapse–free survival in patients with localized prostate cancer.

]]> FDA Approves Immunotherapy to Reduce Chronic GVHD in Patients Undergoing Stem Cell Transplant https://ascopost.com/news/july-2026/fda-approves-immunotherapy-to-reduce-chronic-gvhd-in-patients-undergoing-stem-cell-transplant/ Wed, 01 Jul 2026 03:03:47 +00:00 The ASCO Post The FDA approved allogeneic regulatory T-cell–based immunotherapy with hematopoietic stem and progenitor cell and T cells-vldq (Tregzi) for use in matched donor hematopoietic stem cell transplantation with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution, and to improve chronic graft-vs-host disease (GHVD)-free survival in the treatment of adults with hematologic malignancies.

]]> TAPUR Marks a Decade of Innovation https://ascopost.com/issues/june-25-2026/tapur-marks-a-decade-of-innovation/ Wed, 01 Jul 2026 03:45:52 +00:00 The ASCO Post Richard L. Schilsky, MD, FACP, FSCT, FASCO, discusses how the TAPUR study is turning genomic insights into real-world treatment options for patients who have exhausted their treatment possibilities, the potential future role of artificial intelligence in the study, and what’s ahead for the TAPUR study.

]]>